Hengrui Medicine: Received 6 drug clinical trial approval letters.

Jiangsu Hengrui Medicine announced that the company and its subsidiaries have received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for six drugs, including SHR2554 tablets and SHR-A1811 for injection, and will soon begin clinical trials. These drugs include new oral EZH2 inhibitors SHR2554 tablets, antibody-drug conjugates targeting HER2 for injection SHR-A1811, antibody-drug conjugates targeting Nectin-4 for injection SHR-A2102, humanized anti-PD-L1 monoclonal antibody atezolizumab injection, antibody-drug conjugates targeting Claudin18.2 for injection SHR-A1904, and the anti-PD-L1/TGF-RII bifunctional fusion protein SHR-1701 injection. The accumulated research and development investment for these projects are approximately 180 million yuan for SHR2554 tablets, 1.17 billion yuan for SHR-A1811 for injection, 205 million yuan for SHR-A2102 for injection, 887 million yuan for atezolizumab injection, 143 million yuan for SHR-A1904 for injection, and 674 million yuan for SHR-1701 injection.